Longevity science

Northwestern University scientists have developed a new family of compounds that could slow the progression of Parkinson’s disease.

 

Parkinson’s, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease.

 

The compounds work by blocking calcium. The compounds target and shut a relatively rare membrane protein that allows calcium to flood into dopamine neurons.

 

 

Alpha lipoic acid (ALA) is a potent antioxidant also used by the body to convert blood sugar into energy.

 

Emerging research indicates that ALA may have neuroprotective qualities and help to repair nerve damage and maintain healthy vision.

 

ALA combines synergistically with both glutathione and CoQ10 to maximize free radical protection...

 

These are just two of the mounting studies on ALA and glucose management:

 

--ALA helps prevent the oxidative stress that is linked to impaired glucose management.

http://www.ncbi.nlm.nih.gov/pubmed/21255807

--It may also help maintain healthy fasting glucose levels http://www.ncbi.nlm.nih.gov/pubmed/22374556